ICON Public (NASDAQ:ICLR) Price Target Lowered to $280.00 at JPMorgan Chase & Co.

ICON Public (NASDAQ:ICLR) had its price target decreased by JPMorgan Chase & Co. from $375.00 to $280.00 in a research report released on Friday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical research company’s stock.

ICLR has been the topic of a number of other reports. Robert W. Baird downgraded shares of ICON Public from an “outperform” rating to a “neutral” rating and set a $340.00 price objective on the stock. in a research report on Thursday, October 24th. Baird R W cut shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. StockNews.com lowered shares of ICON Public from a “buy” rating to a “hold” rating in a research report on Thursday, September 19th. The Goldman Sachs Group reduced their target price on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a report on Friday. Finally, Evercore ISI cut their price objective on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Four analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $304.27.

ICON Public Trading Up 4.5 %

Shares of ICON Public stock opened at $230.50 on Friday. The firm has a market cap of $19.02 billion, a PE ratio of 26.86, a PEG ratio of 1.35 and a beta of 1.22. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.31 and a quick ratio of 1.31. ICON Public has a 1 year low of $220.01 and a 1 year high of $347.72. The company has a 50 day simple moving average of $295.86 and a two-hundred day simple moving average of $309.61.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The business had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the previous year, the firm posted $3.10 earnings per share. The company’s revenue was down 1.2% compared to the same quarter last year. Analysts expect that ICON Public will post 14.53 earnings per share for the current fiscal year.

Institutional Trading of ICON Public

Large investors have recently made changes to their positions in the stock. Ashton Thomas Private Wealth LLC bought a new position in ICON Public in the second quarter worth about $54,000. ORG Partners LLC purchased a new stake in ICON Public in the 2nd quarter worth approximately $59,000. Whittier Trust Co. of Nevada Inc. raised its stake in shares of ICON Public by 410.8% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 189 shares of the medical research company’s stock worth $63,000 after buying an additional 152 shares during the period. GAMMA Investing LLC raised its stake in shares of ICON Public by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock worth $82,000 after buying an additional 87 shares during the period. Finally, EverSource Wealth Advisors LLC raised its stake in shares of ICON Public by 17.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock worth $95,000 after buying an additional 42 shares during the period. 95.61% of the stock is owned by hedge funds and other institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.